Breakthrough Pill Doubles Survival Time for Advanced Pancreatic Cancer Patients

A New Dawn in Pancreatic Cancer Treatment

Researchers have announced a significant breakthrough in the fight against one of medicine's most formidable enemies. An experimental oral medication has demonstrated the ability to nearly double survival time in patients battling advanced pancreatic cancer — a disease that has long resisted meaningful therapeutic progress.

The findings, published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago, have sparked genuine optimism among oncologists worldwide.

What Is Daraxonrasib and How Does It Work?

The drug at the center of this development is called daraxonrasib. It works by targeting and blocking a mutated protein responsible for driving tumor growth in more than 90% of pancreatic cancer cases. This protein, linked to mutations in the RAS gene family — particularly KRAS mutations — had been considered virtually "undruggable" for decades due to its structural complexity, which made it difficult for conventional medications to bind to it effectively.

Revolution Medicines, the company behind the drug, engineered a solution using what scientists describe as a molecular glue mechanism. This approach allows the drug to bind across multiple KRAS subtypes simultaneously, representing a fundamentally different strategy compared to earlier cancer therapies.

"This thing works drastically differently," said Dr. Andrew Coveler of the Fred Hutchinson Cancer Center.

The Clinical Trial Results

The clinical study enrolled 500 patients with metastatic pancreatic cancer — meaning the disease had already spread — whose tumors had stopped responding to previous treatments. Participants were randomly assigned to receive either daraxonrasib daily or additional rounds of chemotherapy.

The results were striking:

• Patients taking daraxonrasib survived a median of 13.2 months
• Those receiving chemotherapy survived a median of just 6.7 months
• Patients on the new drug reported less pain and a better quality of life
• Tumor shrinkage was observed, and many patients remained on the drug when the data was collected

What Doctors Are Saying

Dr. Zev Wainberg of UCLA, one of the study's lead researchers, acknowledged that while the drug does not cure pancreatic cancer, it represents "a very large step forward."

The emotional weight of these results resonated deeply with clinicians. Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the study, admitted she was moved to tears upon reviewing the data. "Patients stayed on this treatment because it was providing durable and meaningful benefit to them," she said.

Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the findings at ASCO, stated that daraxonrasib should become "a new standard of care" for previously treated metastatic pancreatic cancer.

Side Effects and Tolerability

The drug was generally better tolerated than chemotherapy, though it does carry some notable side effects. The most clinically significant include:

• Skin rash, which can become severe in some patients
• Mouth sores

Despite these effects, patients remained on the treatment considerably longer than those in the chemotherapy group, suggesting that the benefits outweighed the drawbacks for many.

Regulatory Status and Patient Access

Revolution Medicines funded the clinical trial, and the U.S. Food and Drug Administration has indicated it will expedite its review of daraxonrasib. In the meantime, the FDA has authorized an expanded access program, allowing eligible patients to use the experimental drug before full approval is granted.

The drug has already gained broader public attention after former U.S. Senator Ben Sasse spoke publicly on 60 Minutes about his personal experience with the medication, describing a noticeable reduction in pain. His account has prompted a surge in inquiries to oncologists as the expanded access program rolls out.

Why Pancreatic Cancer Is So Difficult to Treat

Pancreatic cancer carries one of the lowest survival rates of any major cancer type. The American Cancer Society estimates that approximately 67,000 new cases will be diagnosed in the United States this year, with more than 52,000 deaths expected. The five-year survival rate stands at just 13%.

A major reason for this grim outlook is that the disease typically goes undetected until it has already spread to other organs. Unlike breast, lung, or colorectal cancers — which have benefited from a broad range of treatment innovations — pancreatic cancer has seen comparatively little therapeutic advancement.

What Comes Next

Researchers are already planning next steps to build on this momentum. Key areas of investigation include:

• Determining whether daraxonrasib performs better against specific KRAS subtypes
• Exploring the drug's effectiveness earlier in the disease course
• Assessing whether tumor shrinkage might make more patients eligible for surgery
• Investigating vaccines designed to prevent recurrence after surgery by training the immune system to recognize mutated proteins

With dozens of experimental therapies currently in development and this landmark result now in hand, cancer specialists are cautiously hopeful that the long stagnation in pancreatic cancer treatment may finally be coming to an end.

"Having treated pancreatic cancer for 16 years, I actually started crying," Dr. Shroff said — a sentiment that speaks volumes about the significance of this moment in oncology.